Background The underlying change of gene network expression of Guillain-Barré syndrome (GBS) remains elusive. We sought to identify GBS-associated gene networks and signaling pathways by analyzing the transcriptional profile of leukocytes in the patients with GBS. Methods and Findings Quantitative global gene expression microarray analysis of peripheral blood leukocytes was performed on 7 patients with GBS and 7 healthy controls. Gene expression profiles were compared between patients and controls after standardization. The set of genes that significantly correlated with GBS was further analyzed by Ingenuity Pathways Analyses. 256 genes and 18 gene networks were significantly associated with GBS (fold change ≥2, P<0.05). FOS, PTGS2, HMGB2 and MMP9 are the top four of 246 significantly up-regulated genes. The most significant disease and altered biological function genes associated with GBS were those involved in inflammatory response, infectious disease, and respiratory disease. Cell death, cellular development and cellular movement were the top significant molecular and cellular functions involved in GBS. Hematological system development and function, immune cell trafficking and organismal survival were the most significant GBS-associated function in physiological development and system category. Several hub genes, such as MMP9, PTGS2 and CREB1 were identified in the associated gene networks. Canonical pathway analysis showed that GnRH, corticotrophin-releasing hormone and ERK/MAPK signaling were the most significant pathways in the up-regulated gene set in GBS. Conclusions This study reveals the gene networks and canonical pathways associated with GBS. These data provide not only networks between the genes for understanding the pathogenic properties of GBS but also map significant pathways for the future development of novel therapeutic strategies.
References
[1]
Hughes RAC, Cornblath DR (2005) Guillain-Barré syndrome. Lancet 366: 1653–1666.
[2]
Sejvar JJ, Baughman AL, Wise M, Morgan OW (2011) Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 36: 123–133.
[3]
Cosi V, Versino M (2006) Guillain-Barré syndrome. Neurol Sci 27: Suppl 1S47–51.
[4]
Hughes RA, Rees JH (1997) Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis 176: Suppl 2S92–98.
[5]
Kang JH, Sheu JJ, Lin HC (2010) Increased risk of Guillain-Barré syndrome following recent herpes zoster: A population-based study across Taiwan. Clin Infect Dis 51: 525–530.
[6]
Rees JH, Soudain SE, Gregson NA, Hughes RA (1995) Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 333: 1374–1379.
[7]
Wim Ang C, Jacobs BC, Laman JD (2004) The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol 25: 61–66.
[8]
Susuki K, Odaka M, Mori M, Hirata K, Yuki N (2004) Acute motor axonal neuropathy after Mycoplasma infection: Evidence of molecular mimicry. Neurology 62: 949–956.
[9]
Kwa MSG, van Schaik IN, Brand A, Baas F, Vermeulen M (2001) Investigation of serum response to PMP22, connexin 32 and P0 in inflammatory neuropathies. J Neuroimmunol 116: 220–225.
[10]
Kusunoki S, Kaida K (2011) Antibodies against ganglioside complexes in Guillain-Barré syndromé and related disorders. J Neurochem 116: 828–832.
[11]
Kuijf ML, Samsom JN, van Rijs W, Bax M, Huizinga R, et al. (2010) TLR4-mediated sensing of Campylobacter jejuni by dendritic cells is determined by sialylation. J Immunol 185: 748–755.
[12]
Hao Q, Saida T, Kuroki S, Nishimura M, Nukina M, et al. (1998) Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter jejuni and other identified infections. J Neuroimmunol 81: 116–126.
[13]
Gabriel CM, Gregson NA, Hughes RAC (2000) Anti-PMP22 antibodies in patients with inflammatory neuropathy. J Neuroimmunol 104: 139–146.
[14]
Willison HJ, Yuki N (2002) Peripheral neuropathies and anti-glycolipid antibodies. Brain 125: 2591–2625.
[15]
Hafer-Macko CE, Sheikh KA, Li CY, Ho TW, Cornblath DR, et al. (1996) Immune attack on the schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 39: 625–635.
[16]
Hafer-Macko C, Hsieh ST, Ho TW, Sheikh K, Cornblath DR, et al. (1996) Acute motor axonal neuropathy: An antibody-mediated attack on axolemma. Ann Neurol 40: 635–644.
[17]
Griffin J, Li C, Macko C, Ho T, Hsieh S, et al. (1996) Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol 25: 33–51.
[18]
Creange A, Sharshar T, Planchenault T, Christov C, Poron F, et al. (1999) Matrix metalloproteinase-9 is increased and correlates with severity in Guillain-Barré syndrome. Neurology 53: 1683–1691.
[19]
Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, et al. (2004) Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30: 131–156.
[20]
Asbury AK, Arnason BG, Adams RD (1969) The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine 48: 173–215.
[21]
Prineas JW (1981) Pathology of the Guillain-Barré syndrome. Ann Neurol 9: 6–19.
[22]
Griffin JW, Li CY, Ho TW, Tian M, Gao CY, et al. (1996) Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 39: 17–28.
[23]
Marchiori PE, Dos Reis M, Quevedo ME, Callegaro D, Hirata MT, et al. (1990) Cerebrospinal fluid and serum antiphospholipid antibodies in multiple sclerosis, Guillain-Barré syndrome and systemic lupus erythematosus. Arq Neuropsiquiatr 48: 465–468.
[24]
Petzold A, Hinds N, Murray NF, Hirsch NP, Grant D, et al. (2006) CSF neurofilament levels: A potential prognostic marker in Guillain-Barré syndrome. Neurology 67: 1071–1073.
[25]
Matà S, Galli E, Amantini A, Pinto F, Sorbi S, et al. (2006) Anti-ganglioside antibodies and elevated CSF IgG levels in Guillain-Barré syndrome. Eur J Neurol 13: 153–160.
[26]
Mokuno K, Kiyosawa K, Sugimura K, Yasuda T, Riku S, et al. (1994) Prognostic value of cerebrospinal fluid neuron-specific enolase and S-100b protein in Guillain-Barré syndrome. Acta Neurol Scand 89: 27–30.
[27]
Nishino S, Kanbayashi T, Fujiki N, Uchino M, Ripley B, et al. (2003) CSF hypocretin levels in Guillain-Barré syndrome and other inflammatory neuropathies. Neurology 61: 823–825.
[28]
Nagai A, Murakawa Y, Terashima M, Shimode K, Umegae N, et al. (2000) Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases. Neurology 55: 1828–1832.
[29]
Chiang HL, Lyu RK, Tseng MY, Chang KH, Chang HS, et al. (2009) Analyses of transthyretin concentration in the cerebrospinal fluid of patients with Guillain-Barré syndrome and other neurological disorders. Clin Chim Acta 405: 143–147.
[30]
Jin T, Hu LS, Chang M, Wu J, Winblad B, et al. (2007) Proteomic identification of potential protein markers in cerebrospinal fluid of GBS patients. Eur J Neurol 14: 563–568.
[31]
Chang KH, Lyu RK, Tseng MY, Ro LS, Wu YR, et al. (2007) Elevated haptoglobin level of cerebrospinal fluid in Guillain-Barré syndrome revealed by proteomics analysis. Proteomics Clin Appl 1: 467–475.
[32]
D'Aguanno S, Franciotta D, Lupisella S, Barassi A, Pieragostino D, et al. (2010) Protein profiling of Guillain-Barré syndrome cerebrospinal fluid by two-dimensional electrophoresis and mass spectrometry. Neurosci Lett 485: 49–54.
[33]
Weller M, Stevens A, Sommer N, Melms A, Dichgans J, et al. (1991) Comparative analysis of cytokine patterns in immunological, infectious, and oncological neurological disorders. J Neurol Sci 104: 215–221.
[34]
Sainaghi PP, Collimedaglia L, Alciato F, Leone MA, Naldi P, et al. (2010) The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barré syndrome from chronic inflammatory demyelinating polyneuropathy. Cytokine 51: 138–143.
Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM (1978) Controlled trial prednisolone in acute polyneuropathy. Lancet 2: 750–753.
[37]
Wagner EF, Eferl R (2005) Fos/AP-1 proteins in bone and the immune system. Immunol Rev 208: 126–140.
[38]
Wang W, Lin C, Lu D, Ning Z, Cox T, et al. (2008) Chromosomal transposition of PiggyBac in mouse embryonic stem cells. Proc Natl Acad Sci U S A 105: 9290–9295.
[39]
Hu W, Mathey E, Hartung HP, Kieseier BC (2003) Cyclo-oxygenases and prostaglandins in acute inflammatory demyelination of the peripheral nerve. Neurology 61: 1774–1779.
[40]
Miyamoto K, Oka N, Kawasaki T, Miyake S, Yamamura T, et al. (2002) New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis. Muscle Nerve 25: 280–282.
[41]
Miyamoto K, Oka N, Kawasaki T, Satoi H, Akiguchi I, et al. (1998) The effect of cyclooxygenase-2 inhibitor on experimental allergic neuritis. Neuro Report 9: 2331–2334.
[42]
Miyamoto K, Oka N, Kawasaki T, Satoi H, Matsuo A, et al. (1999) The action mechanism of cyclooxygenase-2 inhibitor for treatment of experimental allergic neuritis. Muscle Nerve 22: 1704–1709.
[43]
Kumar K, Singal A, Rizvi MM, Chauhan VS (2008) High mobility group box (HMGB) proteins of Plasmodium falciparum: DNA binding proteins with pro-inflammatory activity. Parasitol Int 57: 150–157.
[44]
Randell SH, Shimizu T, Bakewell W, Ramaekers FC, Nettesheim P (1993) Phenotypic marker expression during fetal and neonatal differentiation of rat tracheal epithelial cells. Am J Respir Cell Mol Biol 8: 546–555.
[45]
Proost P, Van Damme J, Opdenakker G (1993) Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 192: 1175–1181.
[46]
Sharshar T, Durand MC, Lefaucheur JP, Lofaso F, Raphael JC, et al. (2002) MMP-9 correlates with electrophysiologic abnormalities in Guillain-Barré syndrome. Neurology 59: 1649–1651.
[47]
Nyati KK, Prasad KN, Verma A, Paliwal VK (2010) Correlation of matrix metalloproteinases-2 and -9 with proinflammatory cytokines in Guillain-Barré syndrome. J Neurosci Res 88: 3540–3546.
[48]
Kieseier BC, Clements JM, Pischel HB, Wells GM, Miller K, et al. (1998) Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré syndrome. Ann Neurol 43: 427–434.
[49]
Hughes P, Wells G, Clements J, Gearing A, Redford E, et al. (1998) Matrix metalloproteinase expression during experimental autoimmune neuritis. Brain 121: 481–494.
[50]
Redford E, Smith K, Gregson N, Davies M, Hughes P, et al. (1997) A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor-alpha processing attenuates experimental autoimmune neuritis. Brain 120: 1895–1905.
[51]
Zhao XL, Li GZ, Sun B, Zhang ZL, Yin YH, et al. (2010) MMP-mediated cleavage of beta-dystroglycan in myelin sheath is involved in autoimmune neuritis. Biochem Biophys Res Commun 392: 551–556.
Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, et al. (1999) MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 189: 1777–1782.
[54]
Miyake K (2007) Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Sem Immunol 19: 3–10.
[55]
Wang BY, Xu GL, Zhou CH, Tian L, Xue JL, et al. (2010) ΦC31 integrase interacts with TTRAP and inhibits NFκB activation. Mol Biol Rep 37: 2809–2816.
[56]
Pype S, Declercq W, Ibrahimi A, Michiels C, Van Rietschoten JGI, et al. (2000) TTRAP, a novel protein that associates with CD40, tumor necrosis factor (TNF) receptor-75 and TNF receptor-associated factors (TRAFs), and that inhibits nuclear factor-κB activation. J Biol Chem 275: 18586–18593.
[57]
Gerke V, Moss SE (2002) Annexins: From structure to function. Physiol Rev 82: 331–371.
[58]
Kessler C, Junker H, Balseanu TA, Oprea B, Pirici D, et al. (2008) Annexin A3 expression after stroke in the aged rat brain. Rom J Morphol Embryol 49: 27–35.
[59]
Park JE, Lee DH, Lee JA, Park SG, Kim NS, et al. (2005) Annexin A3 is a potential angiogenic mediator. Biochem Biophys Res Commun 337: 1283–1287.
[60]
Mayr B, Montminy M (2001) Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2: 599–609.
[61]
Zhang X, Odom DT, Koo SH, Conkright MD, Canettieri G, et al. (2005) Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci U S A 102: 4459–4464.
[62]
Gómez-Martín D, Díaz-Zamudio M, Crispín JC, Alcocer-Varela J (2009) Interleukin 2 and systemic lupus erythematosus: Beyond the transcriptional regulatory net abnormalities. Autoimmun Rev 9: 34–39.
[63]
Sitaraman SV, Merlin D, Wang L, Wong M, Gewirtz AT, et al. (2001) Neutrophil-epithelial crosstalk at the intestinal lumenal surface mediated by reciprocal secretion of adenosine and IL-6. J Clin Invest 107: 861–869.
[64]
Schroer K, Zhu Y, Saunders MA, Deng WG, Xu XM, et al. (2002) Obligatory role of cyclic adenosine monophosphate response element in cyclooxygenase-2 promoter induction and feedback regulation by inflammatory mediators. Circulation 105: 2760–2765.
[65]
Jander S, Heidenreich F, Stoll G (1993) Serum and CSF levels of soluble intercellular adhesion molecule-1 (ICAM-1) in inflammatory neurologic diseases. Neurology 43: 1809–1813.
[66]
Del Giudice E, Savoldi G, Notarangelo L, Di Benedetto L, Manganelli F, et al. (2003) Acute inflammatory demyelinating polyradiculoneuropathy associated with perforin-deficient familial haemophagocytic lymphohistiocytosis. Acta P？diatrica 92: 398–401.
[67]
Harness J, McCombe PA (2008) Increased levels of activated T-cells and reduced levels of CD4/CD25+ cells in peripheral blood of Guillain-Barré syndrome patients compared to controls. J Clin Neurosci 15: 1031–1035.
[68]
Weishaupt A, Brück W, Hartung T, Toyka KV, Gold R (2001) Schwann cell apoptosis in experimental autoimmune neuritis of the Lewis rat and the functional role of tumor necrosis factor-α. Neurosci Lett 306: 77–80.
[69]
？ren A, White LR, Aasly J (2001) Apoptosis in neurones exposed to cerebrospinal fluid from patients with multiple sclerosis or acute polyradiculoneuropathy. J Neurol Sci 186: 31–36.
[70]
Tomaszewska-Zaremba D, Herman A (2009) The role of immunological system in the regulation of gonadoliberin and gonadotropin secretion. Reprod Biol 9: 11–23.
[71]
Battaglia DF, Brown ME, Krasa HB, Thrun LA, Viguie C, et al. (1998) Systemic challenge with endotoxin stimulates corticotropin-releasing hormone and arginine vasopressin secretion into hypophyseal portal blood: Coincidence with gonadotropin-releasing hormone suppression. Endocrinology 139: 4175–4181.
[72]
Dong C, Davis RJ, Flavell RA (2002) MAP kinases in the immune response. Ann Rev Immunol 20: 55–72.
[73]
Sheu JY, Kulhanek DJ, Eckenstein FP (2000) Differential patterns of ERK and STAT3 phosphorylation after sciatic nerve transection in the rat. Exp Neurol 166: 392–402.
[74]
Ogata T, Iijima S, Hoshikawa S, Miura T, Yamamoto S, et al. (2004) Opposing extracellular signal-regulated kinase and Akt pathways control Schwann cell myelination. J Neurosci 24: 6724–6732.
[75]
Harrisingh MC, Perez-Nadales E, Parkinson DB, Malcolm DS, Mudge AW, et al. (2004) The Ras/Raf/ERK signalling pathway drives Schwann cell dedifferentiation. EMBO J 23: 3061–3071.
[76]
Agthong S, Kaewsema A, Tanomsridejchai N, Chentanez V (2006) Activation of MAPK ERK in peripheral nerve after injury. BMC Neurosci 7: 45.
[77]
Asbury AK, Cornblath DR (1990) Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 27: SupplS21–24.
